Scarica l'app Stockscreener
44.01
1.23%
-0.55
Dopo l'orario di chiusura:
44.05
0.04
+0.09%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché NVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Novo Nordisk Adr Borsa (NVO) Ultime notizie
NVO Stock Quote Price and Forecast - CNN
Novo Nordisk stock extends buyback as trial updates and obesity growth shape outlook - ad-hoc-news.de
Novo Nordisk (NYSE: NVO) has bought back 32M shares, with its 12‑month repurchase plan still running - Stock Titan
Novo Nordisk stock heads into the open after a 2.3% slide - ad-hoc-news.de
Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore? - The Motley Fool
Novo Nordisk stock falls as heart drug trials are halted despite pediatric obesity win - AD HOC NEWS
Eli Lilly vs. Novo Nordisk: One Has 39% Upside. I'm Picking the Other. - Barchart.com
Novo Nordisk A/Sshare repurchase programme - Finansavisen
Novo Nordisk trial shows semaglutide helped 40% of children - Investing.com
Weekly Recap: Oral Wegovy launch in Germany and DKK8.7077bn buyback - TradingView
Novo Nordisk stock dips as Wegovy pill launch in Germany reshapes obesity market - AD HOC NEWS
European ADRs Push Higher In Wednesday Session Led By ING, IHG, And Novo Nordisk - foreignpolicyjournal.com
From hunger to obesity: Developing world faces growing threat to child health By Reuters - Investing.com
European ADRs Inched Higher As Healthcare Led Gains - finimize.com
Novo Nordisk stock reacts to downgrade as oral obesity push advances in Asia - ad-hoc-news.de
European ADRs Slipped In US Trading Late Thursday Morning - Finimize
Novo Nordisk stock softens after Q2 upgrade and dividend payout - ad-hoc-news.de
Weekly Recap: DKK11.2bn B-share buyback and Wegovy UK/UAE uptake - TradingView
Novo Nordisk stock firms as new Wegovy pill study follows raised 2026 outlook - ad-hoc-news.de
Novo Nordisk Shares (NYSE:NVO) Gain 1.9% as $50 Medicare Wegovy Access Trial Challenges Pricing - ts2.tech
Novo Nordisk stock steadies after Q2 growth as buyback milestone is reached - Ad-hoc-news.de
Novo Nordisk stock benefits as France moves to reimburse Wegovy and new obesity trial begins - Ad-hoc-news.de
Novo Nordisk stock holds gains as obesity drug coverage in France supports long-term demand - Ad-hoc-news.de
Novo Nordisk stock steadies after Q2 2026 guidance raise and obesity pill volatility - Ad-hoc-news.de
Weekly Recap: Berenberg cuts NOVO_B and court orders Sun Pharma approval - TradingView
Novo Nordisk (NVO) Sues A Rival Over Obesity Drug Advertising Claims - Sahm
Novo Nordisk stock slips as obesity battle with Lilly and broker downgrade weigh on valuation - Ad-hoc-news.de
Novo Nordisk stock slips after Berenberg downgrade as guidance and competition reshape the outlook - Ad-hoc-news.de
ETFs Investing in Novo Nordisk A/S Sponsored ADR Class B Stocks - TradingView
Why Does Novo Nordisk (NYSE:NVO) Matter to S&P 500 Healthcare? - Kalkine Media
Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule - Sahm
EBITDA per share of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVO.CI - TradingView
Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B Revenue Breakdown – BCBA:NVO.CI - TradingView
Preferred dividends of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVO.CI - TradingView
Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B - TradingView
Novo Nordisk NVO: $47.26 After Guidance Raise, Bull $64 - FinanceFeeds
Novo Nordisk Share Price Forecast | Q2 Earnings, Raised Guidance - Capital.com
Novo Nordisk's Track Record of Internal Innovation Supports a Wide Moat, but Diversification Needed - Morningstar
Novo Nordisk (CPH:NOVO-B; NYSE:NVO) ADR drops after Q2 results outpace forecasts, paving way for possible rebound in Copenhagen - TechStock²
Novo Nordisk reports adjusted operating profit of DKK 33,389 million for Q2 2026 and raises full-year outlook - Finansavisen
Novo Nordisk raises adjusted sales and adjusted operating profit outlook for 2026 - Finansavisen
Novo Nordisk (NYSE: NVO) updates DKK 7,533,256,457 share repurchases - Stock Titan
Weight loss stock wars: Key metrics to watch in Eli Lilly and Novo Nordisk results - Investing.com
Novo Nordisk (NYSE:NVO) Ziltivekimab Trial Fails In Late Stage Cardiovascular Study - Sahm
European ADRs Slipped In US Trading Friday Morning - Finimize
Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation - Finansavisen
Novo Nordisk shares fall after ZEUS trial disappointment highlights 94% sales reliance - TechStock²
Novo Nordisk must face fraud lawsuit over CagriSema trial, judge rules - Investing.com Nigeria
2.25%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):